Taking NIPT to the Next Level: Detection of Fetal Trisomy by qPCR

Friday, 25 May 2018 at 12:35

Add to Calendar ▼2018-05-25 12:35:002018-05-25 13:35:00Europe/LondonTaking NIPT to the Next Level: Detection of Fetal Trisomy by qPCRBiomarkers - From Research To Commercialization in BengaluruBengaluruSELECTBIOenquiries@selectbiosciences.com

Michael Lutz, CEO, LifeCodexx

Michael Lutz

Michael Lutz is an experienced biotech entrepreneur who has extensive experience in the build-up and management of biotech companies. Following various management positions at Novartis Pharma and Evotec Michael has successfully built up six biotech companies over the last 10 years. Four of these companies were sold to publicly traded biotech companies. His current focus is in the area of prenatal diagnosis where he acts as CEO of LifeCodexx AG since 2010.